Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 38 Records) |
Query Trace: Diarrhea and KRAS[original query] |
---|
A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) 2012 Dec . Kim SH, Shim HS, Cho J, Jeong JH, Kim SM, Hong YK, Sung JH, Ha SJ, Kim HR, Chang H, Kim JH, Tania C, Cho BC |
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Mar 24 (3): 718-25. Helbling D, Bodoky G, Gautschi O, Sun H, Bosman F, Gloor B, Burkhard R, Winterhalder R, Madlung A, Rauch D, Saletti P, Widmer L, Borner M, Baertschi D, Yan P, Benhattar J, Leibundgut E O, Bougel S, Koeberle |
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jun 19 (11): 3068-77. Socinski Mark A, Goldman Jonathan, El-Hariry Iman, Koczywas Marianna, Vukovic Vojo, Horn Leora, Paschold Eugene, Salgia Ravi, West Howard, Sequist Lecia V, Bonomi Philip, Brahmer Julie, Chen Lin-Chi, Sandler Alan, Belani Chandra P, Webb Timothy, Harper Harry, Huberman Mark, Ramalingam Suresh, Wong Kwok-Kin, Teofilovici Florentina, Guo Wei, Shapiro Geoffrey |
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Apr 31 (11): 1405-14. Argiris Athanassios, Ghebremichael Musie, Gilbert Jill, Lee Ju-Whei, Sachidanandam Kamakshi, Kolesar Jill M, Burtness Barbara, Forastiere Arlene |
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC cancer 2016 16 412. Adenis Antoine, de la Fouchardiere Christelle, Paule Bernard, Burtin Pascal, Tougeron David, Wallet Jennifer, Dourthe Louis-Marie, Etienne Pierre-Luc, Mineur Laurent, Clisant Stéphanie, Phelip Jean-Marc, Kramar Andrew, Andre Thier |
Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis. Meta gene 2016 Sep 9 110-9. Zhou Mingyi, Yu Ping, Hou Kezuo, Fu Lingyu, Chen Ying, Qu Jinglei, Qu Xiujuan, Liu Yunpeng, Zhang Jingdo |
A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study). Oncology 2016 May . Yoshida Motoki, Takagane Akinori, Miyake Yasuhiro, Shimada Ken, Nagata Naoki, Sato Atsushi, Ogata Yutaka, Fukunaga Mutsumi, Otsuka Koki, Takahashi Takao, Matsumoto Hidetomo, Kagimura Tatsuo, Tsuji Akihi |
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clinical colorectal cancer 2016 Mar . Bowles Daniel W, Kochenderfer Mark, Cohn Allen, Sideris Lucas, Nguyen Nghia, Cline-Burkhardt Vivian, Schnadig Ian, Choi Minsig, Nabell Lisle, Chaudhry Arvind, Ruxer Robert, Ucar Antonio, Hausman Diana, Walker Luke, Spira Alexander, Jimeno Anton |
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2015 Dec 10 (12): 1745-53. Paz-Ares Luis, Hirsh Vera, Zhang Li, de Marinis Filippo, Yang James Chih-Hsin, Wakelee Heather A, Seto Takashi, Wu Yi-Long, Novello Silvia, Juhász Erszébet, Arén Osvaldo, Sun Yan, Schmelter Thomas, Ong Teng Jin, Peña Carol, Smit Egbert F, Mok Tony |
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget 2017 Aug 8 (34): 57528-57536. Kim Lucia, Saieg Mauro, Di Maio Massimo, Gallo Ciro, Butts Charles, Ciardiello Fortunato, Feld Ronald, Cheng Dengxiao, Gebbia Vittorio, Burgio Marco Angelo, Alam Yasmin, Signoriello Simona, Rossi Antonio, Leighl Natasha, Maione Paolo, Morabito Alessandro, Liu Geoffrey, Tsao Ming-Sound, Perrone Francesco, Gridelli Cesa |
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 04 13 (4): 576-584. Felip Enriqueta, Barlesi Fabrice, Besse Benjamin, Chu Quincy, Gandhi Leena, Kim Sang-We, Carcereny Enric, Sequist Lecia V, Brunsvig Paal, Chouaid Christos, Smit Egbert F, Groen Harry J M, Kim Dong-Wan, Park Keunchil, Avsar Emin, Szpakowski Sebastian, Akimov Mikhail, Garon Edward |
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget 2017 Sep 8 (41): 69651-69662. Leighl Natasha B, Tsao Ming-Sound, Liu Geoffrey, Tu Dongsheng, Ho Cheryl, Shepherd Frances A, Murray Nevin, Goffin John R, Nicholas Garth, Sakashita Shingo, Chen Zhuo, Kim Lucia, Powers Jean, Seymour Lesley, Goss Glenwood, Bradbury Penelope |
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy. Oncotarget 2017 1 8 (23): 37875-37883. Bruera Gemma, Russo Antonio, Galvano Antonio, Rizzo Sergio, Ricevuto Enri |
Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis. Cancer management and research 2018 10 2915-2924. Chen Duke, Wu Yu-Shen, Lin Huapeng, Wang Yihan, Li Longhao, Zhang T |
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. Cancer chemotherapy and pharmacology 2018 Jul . Furuse Junji, Kurata Takayasu, Okano Naohiro, Fujisaka Yasuhito, Naruge Daisuke, Shimizu Toshio, Kitamura Hiroshi, Iwasa Tsutomu, Nagashima Fumio, Nakagawa Kazuhi |
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Medical oncology (Northwood, London, England) 2018 May 35 (7): 101. Papaxoinis George, Kotoula Vassiliki, Giannoulatou Eleni, Koliou Georgia-Angeliki, Karavasilis Vasilios, Lakis Sotirios, Koureas Andreas, Bobos Mattheos, Chalaralambous Elpida, Daskalaki Emily, Chatzopoulos Kyriakos, Tsironis George, Pazarli Elisavet, Chrisafi Sofia, Samantas Epaminontas, Kaklamanos Ioannis G, Varthalitis Ioannis, Konstantara Athina, Syrigos Konstantinos N, Pentheroudakis George, Pectasides Dimitrios, Fountzilas Geor |
Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 2018 Jun . Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens |
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Mar . Hill Andrew G, Findlay Michael P, Burge Matthew E, Jackson Christopher, Alfonso Pilar Garcia, Samuel Leslie, Ganju Vinod, Karthaus Meinolf, Amatu Alessio, Jeffery Mark, Bartolomeo Maria Di, Bridgewater John, Coveler Andrew L, Hidalgo Manuel, Kapp Amy V, Sufan Roxana I, McCall Bruce B, Hanley William D, Penuel Elicia M, Pirzkall Andrea, Tabernero Jos |
Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 2 36 (13): 1291-1299. Juric Dejan, Rodon Jordi, Tabernero Josep, Janku Filip, Burris Howard A, Schellens Jan H M, Middleton Mark R, Berlin Jordan, Schuler Martin, Gil-Martin Marta, Rugo Hope S, Seggewiss-Bernhardt Ruth, Huang Alan, Bootle Douglas, Demanse David, Blumenstein Lars, Coughlin Christina, Quadt Cornelia, Baselga Jo |
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. Cancer research and treatment 2018 Jan . Yoo Changhoon, Han Boram, Kim Hyeong Su, Kim Kyu-Pyo, Kim Deokhoon, Jeong Jae Ho, Lee Jae-Lyun, Kim Tae Won, Kim Jung Han, Choi Dae Ro, Ha Hong Il, Seo Jinwon, Chang Heung-Moon, Ryoo Baek-Yeol, Zang Dae You |
Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer. Clinical lung cancer 2019 2 20 (3): e317-e328. Nokihara Hiroshi, Nishio Makoto, Yamamoto Noboru, Fujiwara Yutaka, Horinouchi Hidehito, Kanda Shintaro, Horiike Atsushi, Ohyanagi Fumiyoshi, Yanagitani Noriko, Nguyen Linh, Yaron Yifah, Borgman Anne, Tamura Tomohi |
Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Apr . Wu Christina, Williams Terence M, Robb Ryan, Webb Amy, Wei Lai, Chen Wei, Mikhail Sameh, Ciombor Kristen K, Cardin Dana B, Timmers Cynthia, Krishna Somashekar G, Arnold Mark, Harzman Alan, Abdel-Misih Sherif, Roychowdhury Sameek, Bekaii-Saab Tanios, Wuthrick Ev |
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The oncologist 2020 12 26 (4): 290-e545. van Brummelen Emilie M J, Huijberts Sanne, van Herpen Carla, Desar Ingrid, Opdam Frans, van Geel Robin, Marchetti Serena, Steeghs Neeltje, Monkhorst Kim, Thijssen Bas, Rosing Hilde, Huitema Alwin, Beijnen Jos, Bernards Rene, Schellens J |
Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. International journal of cancer 2020 12 . Jensen Benny Vittrup, Schou Jakob V, Yilmaz Mette, Johannesen Helle H, Skougaard Kristin, Linnemann Dorte, Hogdall Estrid V, Larsen Finn O, Johansen Julia S, Pfeiffer Per, Nielsen Dorte |
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Jan . Dhani Neesha C, Hirte Hal W, Wang Lisa, Burnier Julia V, Jain Angela, Butler Marcus O, Welch Stephen, Fleming Gini F, Hurteau Jean, Matsuo Koji, Matei Daniela, Jimenez Waldo, Johnston Carolyn, Cristea Mihaela, Tonkin Katia, Ghatage Prafull, Lheureux Stephanie, Mehta Anjali, Quintos Judy, Tan Qian, Kamel-Reid Suzanne, Ludkovski Olga, Tsao Ming-Sound, Wright John J, Oza Amit |
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clinical colorectal cancer 2021 Jul . Alshammari Kanan, Aung Kyaw L, Zhang Tong, Razak Albiruni R A, Serra Stefano, Stockley Tracy, Wang Lisa, Nguyen Jessica, Spreafico Anna, Hansen Aaron R, Zwir Dave, Siu Lillian L, Bedard Philippe |
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA oncology 2021 Aug . Martinelli Erika, Martini Giulia, Famiglietti Vincenzo, Troiani Teresa, Napolitano Stefania, Pietrantonio Filippo, Ciardiello Davide, Terminiello Marinella, Borrelli Carola, Vitiello Pietro Paolo, De Braud Filippo, Morano Federica, Avallone Antonio, Normanno Nicola, Nappi Anna, Maiello Evaristo, Latiano Tiziana, Falcone Alfredo, Cremolini Chiara, Rossini Daniele, Santabarbara Giuseppe, Pinto Carmine, Santini Daniele, Cardone Claudia, Zanaletti Nicoletta, Di Liello Alessandra, Renato Daniela, Esposito Lucia, Marrone Francesca, Ciardiello Fortuna |
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO precision oncology 2022 2 6 e2100424. Krop Ian E, Jegede Opeyemi A, Grilley-Olson Juneko E, Lauring Josh D, Mitchell Edith P, Zwiebel James A, Gray Robert J, Wang Victoria, McShane Lisa M, Rubinstein Larry V, Patton David, Williams P Mickey, Hamilton Stanley R, Kono Scott A, Ford James M, Garcia Agustin A, Sui Xingwei D, Siegel Robert D, Slomovitz Brian M, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith |
Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042). Clinical cancer research : an official journal of the American Association for Cancer Research 2023 5 . Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Gregory J Gerstner, Timothy F Burns, Asma Taj, Wallace L Akerley, Konstantin H Dragnev, Noel Laudi, Mary W Redman, Jhanelle E Gray, David R Gandara, Karen Kel |
Efficacy and toxicity of drugs targeting KRAS mutation in non-small cell lung cancer: a meta-analysis. Expert review of anticancer therapy 2023 11 . Wei Luo, Jing Zhu, Wenxue Zhang, Airu Yu, Wei Zhou, Ke |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 25, 2024
- Content source: